Award Number: W81XWH-05-1-0137

TITLE: A Role for TACI in Prostate Neoplasia

PRINCIPAL INVESTIGATOR: Gotz-Ulrich von Bulow, Ph.D.

CONTRACTING ORGANIZATION: Indiana University
Indianapolis, IN 46202-5167

REPORT DATE: January 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
2. REPORT TYPE | Annual
3. DATES COVERED (From - To) | 01-01-2007
4. TITLE AND SUBTITLE | A Role for TACI in Prostate Neoplasia

5a. CONTRACT NUMBER | 
5b. GRANT NUMBER | W81XWH-05-1-0137
5c. PROGRAM ELEMENT NUMBER | 
5d. PROJECT NUMBER | 
5e. TASK NUMBER | 
5f. WORK UNIT NUMBER | 

6. AUTHOR(S) | Gotz-Ulrich von Bulow, Ph.D.

E-Mail: gvonbulo@iupui.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) | Indiana University
Indianapolis, IN 46202-5167

8. PERFORMING ORGANIZATION REPORT NUMBER | 

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) | U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR’S ACRONYM(S) | USAMRMC

11. SPONSOR/MONITOR’S REPORT NUMBER(S) | 

12. DISTRIBUTION / AVAILABILITY STATEMENT | Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES – Original contains colored plates: ALL DTIC reproductions will be in black and white.

14. ABSTRACT | No abstract provided.

15. SUBJECT TERMS | No subject terms provided.

16. SECURITY CLASSIFICATION OF:

| a. REPORT | U |
| b. ABSTRACT | U |
| c. THIS PAGE | U |

17. LIMITATION OF ABSTRACT | UU
18. NUMBER OF PAGES | 4
19a. NAME OF RESPONSIBLE PERSON | USAMRMC
19b. TELEPHONE NUMBER (include area code) | 

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18
Table of Contents

Introduction ................................................................................................................. 4

Body ............................................................................................................................ 4

Key Research Accomplishments .......................................................................... 4

Reportable Outcomes .............................................................................................. 4

Conclusions ............................................................................................................. 4

References ............................................................................................................... 4

Appendices ............................................................................................................. 4
Missing Annual Report 12/4/04-12/14/05

Introduction

The goal of this grant was to gain insight into the molecular basis of prostate cancer. Preliminary evidence suggested that the taci gene is expressed in normal prostate tissues, but not in prostate tumor cells. We had proposed the APRIL provides a proliferative signal to normal prostate epithelial cells by means of an unknown receptor.

Body

To determine the role of APRIL and TACI in prostate tumor growth, we cultured LNCaP, PC3 and DU145 prostate cancer cell lines and titrated the effects of recombinant APRIL and TACL-Ig on cell growth as determined by MTT assay, DNA content of cells and Annexin V binding assays;

Reportable Outcomes

(a) According to our hypothesis we anticipated that the addition of recombinant APRil would enhance cell growth whereas the addition of TACi-IL would either reduce cell growth or induce apoptosis. This did not happen and for all four cell lines tested we did not see any significant changes in relative cell number (as determined by MTT reduction), nor did we see any significant changes in the relative numbers of hyperdiploid cells as determined by propidium iodide flow cytometry. These experiments were repeated several times with similar results. To overcome the possibility that the cells were already maximally stimulated in the presence of fetal calf serum, we repeated the MTT experiments in either serum-free conditions, or in medium with 1% fetal calf serum. Although the MTT values were reduced overall, there was no significant difference observed when titrating in either APRIL or TACI-Ig. We included the titration with BAFF since it is also a TACI ligand, but similar negative results were obtained with this cytokine. When performing the apoptosis assays with propidium iodide and annexin V staining, we encountered a pitfall in that we were not able to separate the cells from the monolayer into individual cells for flow cytometry using EDTA or trypsin without affecting the viability of the cells (and thereby propidium iodide staining). Overall these types of experiments were not very reproducible and were therefore abandoned as unreliable.

Conclusions

We will not perform the experiments to determine the effect of systemic TACI!g administration on the growth of LNCaP cells in nude mice because of our negative results. We will continue to look at growth characteristics in the presence of doxycyclin when compared with the parental cell lines.

References: None

Appendices: None